Get the Stockscreener App
4.16
11.83%
0.44
Avita Medical Inc stock is traded at $4.16, with a volume of 362.38K.
It is up +11.83% in the last 24 hours and up +26.06% over the past month.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$3.72
Open:
$3.66
24h Volume:
362.38K
Relative Volume:
1.71
Market Cap:
$126.85M
Revenue:
$50.14M
Net Income/Loss:
$-35.38M
P/E Ratio:
-2.9714
EPS:
-1.4
Net Cash Flow:
$-39.46M
1W Performance:
+6.67%
1M Performance:
+26.06%
6M Performance:
-27.78%
1Y Performance:
-52.62%
1-Day Range:
$3.52
$4.43
1-Week Range:
$3.52
$4.43
52-Week Range:
$3.22
$11.25
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
4.16 | 113.43M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Upgrade | BTIG Research | Sell → Neutral |
| Aug-08-25 | Downgrade | BTIG Research | Neutral → Sell |
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth - Investing.com Nigeria
Broker tips 25% upside for this ASX healthcare stock following FY25 earnings results - MSN
Avita's Road to Profitability Is in Sight - Morningstar
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026 - Investing.com Canada
AVITA Medical (RCEL) Reports Strong Q4 2025 Performance - GuruFocus
Avita Medical Q4 Earnings Call Highlights - MarketBeat
AVITA Medical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AVITA Medical (RCEL) Q4 2025 Earnings Transcript - The Globe and Mail
Avita Medical (RCEL) Reports Lower Q4 Revenue Amidst Operational Transition - GuruFocus
Avita Medical earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
AVITA Medical to Announce Q4 Earnings on February 12 - Intellectia AI
Avita Medical (NASDAQ:RCEL) Issues Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
AVITA Medical, Inc. SEC 10-K Report - TradingView
AVITA Medical Q4 Earnings Summary & Key Takeaways - Benzinga
AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - bdtonline.com
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 earnings call transcript - MSN
Is AVITA Medical Inc. forming a bullish divergenceEarnings Recap Summary & Fast Entry and Exit Trade Plans - mfd.ru
Bull Run: Can AVITA Medical Inc weather a recessionMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Is AVITA Medical Inc. stock a buy before product launchesTrade Risk Report & Fast Exit and Entry Trade Guides - mfd.ru
Lake Street Raises Price Target on AVITA Medical, Inc. (RCEL) to $3.50, Maintains Hold Rating - Finviz
Lake Street raises price target on AVITA Medical, Inc. (RCEL) to $3.50, maintains hold rating - MSN
Avita Medical (RCEL) to Release Quarterly Earnings on Thursday - MarketBeat
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
AVITA Medical, Inc.'s (NASDAQ:RCEL) Shift From Loss To Profit - Yahoo Finance
Avita Medical Stock: Skin Regeneration Platform Is Set Up For A Turnaround (NASDAQ:RCEL) - Seeking Alpha
Buy Signal: Can AVITA Medical Inc weather a recession2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Insider Buy: Is Ellomay Capital Ltd a speculative investmentPortfolio Risk Report & High Conviction Trade Alerts - baoquankhu1.vn
Aug Summary: What is NVAWWs P E ratio telling usMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
AVITA Medical (RCEL) Analyst Rating: Maintained 'Buy' with $10 P - GuruFocus
D. Boral Capital Reaffirms Buy Rating for Avita Medical (NASDAQ:RCEL) - MarketBeat
New Highs: Will AVITA Medical Inc benefit from rate cuts2025 Year in Review & Safe Capital Allocation Plans - baoquankhu1.vn
AVITA Medical (RCEL) Showcases Breakthrough Data at 2026 Burn Sy - GuruFocus
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies - Investing News Network
First three-part AVITA burn care path cuts painful dressing changes - stocktitan.net
There's No Escaping AVITA Medical, Inc.'s (NASDAQ:RCEL) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Momentum Shift: Can AVITA Medical Inc maintain sales growth2025 Key Lessons & Low Drawdown Trading Strategies - baoquankhu1.vn
Volatility Watch: Is AVITA Medical Inc stock forming a triangle patternWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
AVITA Medical, Inc.'s (NASDAQ:RCEL) Path To Profitability - simplywall.st
RCEL Analyst Rating Update: Lake Street Raises Price Target | RC - GuruFocus
AVITA Medical (ASX:AVH) Posts Revenue Growth and Advances Clinical Pipeline Ahead of Key Data in 2026 - Kalkine Media
AVITA Medical (RCEL): Analyst Lowers Price Target, Maintains Buy Rating | RCEL Stock News - GuruFocus
D. Boral Capital Issues Pessimistic Forecast for Avita Medical (NASDAQ:RCEL) Stock Price - MarketBeat
RCEL: 2026 guidance targets $80–$85M revenue, driven by clinical innovation and focused execution - TradingView — Track All Markets
Aug Drivers: Does AUTAP have strong EBITDA marginsJuly 2025 Outlook & Safe Entry Point Identification - baoquankhu1.vn
AVITA Medical, Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook - marketscreener.com
AVITA Medical reports Q4 revenue of $17.6 million, secures new debt - Investing.com Canada
Entry Recap: Should I hold or sell AVITA Medical Inc stock in 2025Analyst Downgrade & Daily Market Momentum Tracking - Bộ Nội Vụ
AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook - Investing News Network
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avita Medical Inc Stock (RCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Toole David D | CFO |
Aug 26 '25 |
Buy |
4.52 |
2,000 |
9,040 |
31,657 |
| McNamara Robert | Director |
Aug 19 '25 |
Buy |
5.00 |
10,000 |
50,000 |
76,771 |
| O'Toole David D | CFO |
Aug 12 '25 |
Buy |
4.81 |
2,000 |
9,620 |
29,657 |
| McNamara Robert | Director |
Mar 06 '25 |
Buy |
8.30 |
11,000 |
91,300 |
56,749 |
| McNamara Robert | Director |
Feb 20 '25 |
Buy |
10.09 |
10,000 |
100,900 |
45,749 |
| O'Toole David D | CFO |
Feb 20 '25 |
Buy |
9.90 |
1,000 |
9,900 |
25,734 |
| O'Toole David D | CFO |
Feb 19 '25 |
Buy |
10.25 |
1,000 |
10,250 |
24,734 |
1.33%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):